PharmaResearch Co

PharmaResearch Co EBIT Margin

The EBIT Margin (Operating Margin) of PharmaResearch Co (214450.KQ) as of Oct 28, 2026 is 39.98 %. In the previous year, EBIT Margin (Operating Margin) was 35.87 % — a change of 11.44% (higher).

EBIT Margin

39.98 %

YoY

11.44%

Last updated:

EBIT Margin (Operating Margin) of PharmaResearch Co is 2025 39.98 % . EBIT Margin (Operating Margin) of PharmaResearch Co was 2024 35.87 % . It decreases by 11.44% higher compared to the previous year.

For PharmaResearch Co, the operating (EBIT) margin of 40.0% is up versus 33.5% a few years ago.

The PharmaResearch Co EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
12.19 KRW
Jan 1, 2019
22.73 KRW
Jan 1, 2020
29.59 KRW
Jan 1, 2021
33.52 KRW
Jan 1, 2022
31.22 KRW
Jan 1, 2023
34.15 KRW
Jan 1, 2024
35.87 KRW
Jan 1, 2025
39.98 KRW
The PharmaResearch Co EBIT Margin history
YEAREBIT MarginYoY
39.98 %+11.44%
35.87 %+5.04%
34.15 %+9.39%
31.22 %-6.86%
33.52 %+13.29%
29.59 %+30.18%
22.73 %+86.43%
12.19 %-52.44%
25.63 %-16.49%
30.69 %-28.55%
42.96 %-6.79%
46.09 %+11,259.94%
0.41 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PharmaResearch Co Stock analysis

What does PharmaResearch Co do? PharmaResearch Co Ltd, identified by the ticker symbol 214450.KQ and ISIN KR7214450009, is a South Korean enterprise operating within the health care sector, specifically in the biotechnology industry. Headquartered in Gangneung, located in the Gangwon-Do province, the company has established itself as a specialized player in the field of marine biotechnology. The firm's core operational focus lies in the research and development of refined raw materials designed for cell and tissue regeneration. This scientific foundation supports the company's broader commercial activities, which include the production and sale of regenerated products across multiple sectors. These product categories encompass pharmaceuticals, medical devices, and cosmetics, reflecting a diverse application of its technological capabilities in health and personal care markets. The company initially entered the public markets through an initial public offering on July 24, 2015, marking a significant milestone in its corporate development and providing a platform for potential growth and capital expansion. While the primary market for its products is the domestic South Korean market, the company's strategic positioning within the biotechnology sector highlights its commitment to leveraging marine resources for advanced biological applications. Beyond its core biotechnology and manufacturing operations, PharmaResearch Co Ltd maintains a diversified business portfolio that includes venture investment and real estate leasing activities. These additional ventures contribute to the company's overall financial structure and operational breadth, although the primary emphasis remains on its scientific research and product development in the regeneration field. The company's digital presence is maintained through its official website at http://pharmaresearch.co.kr/, serving as a resource for stakeholders and partners seeking information on its ongoing projects and corporate updates. As a listed entity on the Korean market, PharmaResearch Co Ltd continues to navigate the competitive landscape of the biotechnology industry, relying on its specialized expertise in marine bio technology to drive innovation and deliver value through its regenerated products and related services. PharmaResearch Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmaResearch Co stock

EBIT Margin (Operating Margin) of PharmaResearch Co is 39.98 % in 2025.

EBIT Margin (Operating Margin) of PharmaResearch Co changed from 35.87 % to 39.98 %, representing a 11.44% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) PharmaResearch Co since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s PharmaResearch Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — PharmaResearch Co

All Key Metrics — PharmaResearch Co